News | March 07, 2024
Briefs: Zydus, Advanced Enzyme Technologies, Link Pharma Chem and ANVISA
ANVISA issues CGMP to Concord Biotech’s Unit I
ANVISA issues CGMP to Concord Biotech’s Unit I
BHL will undertake the development and supply of these molecules
The latest upgraded Tele Clinic is Artificial Intelligence (AI) - driven to provide healthcare facilities in far flung areas of the region, where such facilities are either not available or inadequately available
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Dr. Jitendra Singh inaugurates 300 LPM capacity Oxygen Plant, Day Care Chemotherapy Unit affiliated to Tata Memorial Hospital & Maternal ICU at GMC Kathua
The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States
The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive
Subscribe To Our Newsletter & Stay Updated
